Company

About AionWell

AionWell Inc. is a translational medicine company focused on evidence decisions in early oncology development.

Our focus

Before the next study

A promising result often leaves several studies competing for the same budget. We work with biotech development teams to identify which uncertainty matters to the next choice and which evidence could resolve it.

Our initial focus is biomarker-dependent solid tumor programs, including antibodies and antibody–drug conjugates. Population selection, drug distribution and the interpretation of early signals are recurring questions in that work.

Method

How we work

Start with the decision

Identify who owns the choice, when it must be made and which options are still open.

Show the source

Link each important claim to its source. Keep model assumptions, missing evidence and conflicting observations visible.

Keep judgment accountable

Use AI to organize material and support comparison. Scientific interpretation is reviewed by people, and the sponsor owns the development decision.

Project inquiries

What decision is your team facing?

Discuss a project